Login / Signup

Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group.

Olivier HermineXavier MarietteRaphael PorcherMatthieu Resche-RigonPierre-Louis TharauxPhilippe Ravaudnull null
Published in: The European respiratory journal (2022)
In critically ill patients with COVID-19, anti-IL-6 receptors did not significantly increase the number of patients alive without any NIV or MV by day 14.
Keyphrases
  • end stage renal disease
  • sars cov
  • coronavirus disease
  • chronic kidney disease
  • ejection fraction
  • newly diagnosed
  • prognostic factors
  • quality improvement
  • respiratory syndrome coronavirus